Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

345 ARTÍCULOS , VIENDO DEL 256 AL 270

Language impairment in Alzheimer's disease and benefits of acetylcholinesterase inhibitors

Ferris SH, Farlow M.

Clin Interv Aging. 2013;8:1007-14. doi: 10.2147/CIA.S39959. Epub 2013 Aug 2.

Atypical aging in Down syndrome

Zigman WB.

Dev Disabil Res Rev. 2013;18(1):51-67. doi: 10.1002/ddrr.1128.

Angiotensin-converting enzyme inhibitors and Alzheimer's disease progression in older adults: results from the Réseau sur la Maladie d'Alzheimer Français cohort

Soto ME, van Kan GA, Nourhashemi F, Gillette-Guyonnet S, Cesari M, Cantet C, Rolland Y, Vellas B.

J Am Geriatr Soc. 2013 Sep;61(9):1482-8. doi: 10.1111/jgs.12415. Epub 2013 Sep 3.

[Main interventions for rehabilitation of autobiographical memory in Alzheimer's disease from early to severe stage: a review and new perspectives]

Lalanne J, Piolino P.

Geriatr Psychol Neuropsychiatr Vieil. 2013 Sep;11(3):275-85. doi: 10.1684/pnv.2013.0422.

Psychosis, agitation, and antipsychotic treatment in dementia

Devanand DP.

Am J Psychiatry. 2013 Sep;170(9):957-60. doi: 10.1176/appi.ajp.2013.13060767.

Aphasia(s) in Alzheimer

Teichmann M, Ferrieux S.

Rev Neurol (Paris). 2013 Oct;169(10):680-6. doi: 10.1016/j.neurol.2013.06.001. Epub 2013 Sep 12.

Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials

Yang G, Wang Y, Tian J, Liu JP.

PLoS One. 2013 Sep 23;8(9):e74916. doi: 10.1371/journal.pone.0074916. eCollection 2013.

Antidiabetic drugs and their potential role in treating mild cognitive impairment and Alzheimer's disease

Alagiakrishnan K, Sankaralingam S, Ghosh M, Mereu L, Senior P.

Discov Med. 2013 Dec;16(90):277-86.

New treatment strategies for Alzheimer's disease: is there a hope?

Aprahamian I, Stella F, Forlenza OV.

Indian J Med Res. 2013 Oct;138(4):449-60.

Biomarkers for Alzheimer's disease: showing the way or leading us astray?

Quinn JF.

J Alzheimers Dis. 2013;33 Suppl 1(Suppl 1):S371-6. doi: 10.3233/JAD-2012-129022.

Blood transcriptomic biomarkers of Alzheimer's disease patients treated with EHT 0202

Désiré L, Blondiaux E, Carrière J, Haddad R, Sol O, Fehlbaum-Beurdeley P, Einstein R, Zhou W, Pando MP.

J Alzheimers Dis. 2013;34(2):469-83. doi: 10.3233/JAD-121501.

A conceptual framework and ethics analysis for prevention trials of Alzheimer Disease

Peters KR, Lynn Beattie B, Feldman HH, Illes J.

Prog Neurobiol. 2013 Nov;110:114-23. doi: 10.1016/j.pneurobio.2012.12.001. Epub 2013 Jan 21.

Phenylbutyrate is a multifaceted drug that exerts neuroprotective effects and reverses the Alzheimer´s disease-like phenotype of a commonly used mouse model

Cuadrado-Tejedor M, Ricobaraza AL, Torrijo R, Franco R, Garcia-Osta A.

Curr Pharm Des. 2013;19(28):5076-84. doi: 10.2174/1381612811319280006.

Alzheimer's disease drug development: translational neuroscience strategies

Cummings JL, Banks SJ, Gary RK, Kinney JW, Lombardo JM, Walsh RR, Zhong K.

CNS Spectr. 2013 Jun;18(3):128-38. doi: 10.1017/S1092852913000023. Epub 2013 Mar 11.

The role of cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis. where are we now?

Papaliagkas VT.

Recent Pat CNS Drug Discov. 2013 Apr;8(1):70-8. doi: 10.2174/1574889811308010006.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias